China Pharmaceutical Sector Report 2017 1st Quarter

  • ID: 4392507
  • Report
  • Region: China
  • 60 pages
  • EMIS, A Euromoney Institutional Investor Company
1 of 5
China's Pharmaceutical Sector Is Going Through Transformation And Liberalisation, Which Are Expected To Narrow The Price Gap Between Local And Foreign Drug Manufacturers And To Increase Competition And Sector Consolidation.

FEATURED COMPANIES

  • China Meheco Co Ltd
  • Huadong Medicine Co Ltd
  • MORE
This report provides a complete and detailed analysis of the pharmaceutical sector for China. In-depth business intelligence is presented in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this Report Allows you to do:
  • Understand the key elements at play in the pharmaceutical sector in China
  • Access forecasts for growth in the sector
  • View key data on production and sales for the sector in China
  • Crystallise the forces both driving and restraining this sector in China
  • Build a complete perspective on sector trade, investment and employment
  • Understand the competitive landscape and who the major players are
  • View M&A activity and major deals
  • Gain an understanding of the regulatory environment for the sector in China
  • Build a clear picture of trends and issues for sub-sectors (western medicine, traditional Chinese medicine).
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • China Meheco Co Ltd
  • Huadong Medicine Co Ltd
  • MORE
1. Executive Summary
  • Sector In Numbers
  • Sector Overview
  • Sector Snapshot
  • Driving Forces
  • Restraining Forces
2. Sector In Focus Quarterly Update
  • Quarterly Summary
  • Sector Outlook
  • Sector Highlights
  • Main Sector Indicators
  • Top M&A Deals
  • M&A Activity
3. Competitive Landscape
  • Highlights
  • Top Pharmaceutical Enterprises
  • Top Pharmaceutical Manufacturers
  • Top Pharmaceutical Exporters
  • Top 10 Listed Companies
  • Top Listed Companies
4. Companies In Focus
  • Shanghai Pharmaceuticals Holding Co Ltd
  • Nanjing Pharmaceutical Co Ltd
  • Huadong Medicine Co Ltd
  • China Meheco Co Ltd
  • Kangmei Pharmaceutical Co Ltd
5. Regulatory Environment
  • Government Policy
  • Healthcare Reform
  • Sector Reform
  • Anti-Corruption Policies
6. Western Medicine
  • Highlights
  • Main Indicators By Segment
7. Traditional Chinese Medicine
  • Highlights
  • Main Indicators By Segment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • China Meheco Co Ltd
  • Huadong Medicine Co Ltd
  • MORE
China is the world’s second largest pharmaceutical market after the US and the largest producer and exporter of active pharmaceutical ingredients (APIs) globally. Since it is the world’s most populous country, with a large ageing population, the healthcare and pharmaceutical industries are of key importance to the government, which has launched a series of reforms in both sectors over the last few years. The pharmaceutical sector is going through transformation and liberalisation, which are expected to narrow the price gap between local and foreign drug manufacturers and to increase competition and sector consolidation. Along with the removal of the price cap on drugs in 2015, the government has increased its supervisory role.
Note: Product cover images may vary from those shown
5 of 5
  • Shanghai Pharmaceuticals Holding Co Ltd
  • Nanjing Pharmaceutical Co Ltd
  • Huadong Medicine Co Ltd
  • China Meheco Co Ltd
  • Kangmei Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll